VUMON
LOE Approachingteniposide
NDAINJECTIONINJECTABLEPriority Review
Approved
Jul 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 13h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VUMON (teniposide) is an injectable small-molecule topoisomerase II inhibitor used in oncology to treat pediatric acute lymphoblastic leukemia (ALL) and other hematologic malignancies. It works by inhibiting topoisomerase II, leading to DNA strand breaks and cell death in rapidly dividing cancer cells.
LOE Approaching
Late-stage product with LOE approaching and moderate competitive pressure (30%) suggests team focus is on managed decline and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer
Started Feb 2025
15 enrolled
Extensive-stage Small Cell Lung Cancer (ES-SCLC)Thoracic NeoplasmsLung Neoplasms+1 more
Career Relevance
VUMON offers limited career growth opportunities due to LOE approaching and zero linked job postings; roles available are primarily in commercial maintenance, managed decline, and regulatory compliance rather than expansion or innovation. Assignment to this product may be appropriate for experienced professionals managing mature portfolios or for mid-career professionals seeking specialized oncology expertise in a stable, legacy setting.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.